Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-03-20

Clinical Trial Update: A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) [Phase 1]

View source ↗

Summary

Phase 1 trial updating tirzepatide in participants with type 2 diabetes mellitus has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED | Results posted: 2023-03-20